Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03493516 · ClinicalTrials.gov registry record
Prediction of ARrhythmic Events With Positron Emission Tomography II
A clinical trial of Congestive Heart Failure and Ischemic Cardiomyopathy, sponsored by State University of New York at Buffalo.
- Active
- Registry status
- 302
- Enrollment target
- 1
- Study location
NCT03493516: Active study of Congestive Heart Failure and Ischemic Cardiomyopathy, sponsored by State University of New York at Buffalo.
NCT03493516 is a study of Congestive Heart Failure and Ischemic Cardiomyopathy that is active but no longer recruiting, run by State University of New York at Buffalo. The registered enrollment target is 302 participants, roughly in line with the 324-participant average among 51 other Congestive Heart Failure trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03493516, a study of Congestive Heart Failure and Ischemic Cardiomyopathy, is active but no longer recruiting, sponsored by State University of New York at Buffalo.
- ACTIVE NOT RECRUITING
- Registry status
- 302 participants
- Enrollment target
- 1
- Study location
Study Summary
Sudden cardiac death continues to be a major contributor to mortality in patients with ischemic cardiomyopathy. While implantable defibrillators can prevent death from ventricular arrhythmias, our current approach to identify patients at highest risk primarily rests on demonstrating a reduction in left ventricular ejection fraction less than 35%. The purpose of this observational cohort study is to prospectively test whether this can be enhanced by quantifying the amount of sympathetic denervation, left ventricular end-diastolic volume or brain natriuretic peptide levels.
Primary Outcome
The primary end-point will be SCA or ICD equivalent as used in PAREPET. This will consist of ICD therapies for ventricular fibrillation or ventricular tachycardia \>240 bpm, and adjudicated arrhythmic death using the modified Hinkle-Thaler criteria.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST PET scan quantifying sympathetic denervation using [18F]-LMI1195
Study Locations (1)
New York
- University at Buffalo Clinical and Translational Research Center - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 302 participants |
| Start Date | 2018-04-08 |
| Est. Completion | 2026-12-31 |
What the registry record for NCT03493516 still lists
NCT03493516 is an observational study that tracks outcomes without assigning an intervention. The registered 302 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 324-participant average among 51 other Congestive Heart Failure trials with a reported enrollment target.
The record links to 3 conditions, with Congestive Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which PET scan quantifying sympathetic denervation using [18F]-LMI1195 is the first listed.
NCT03493516 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03493516 about?
NCT03493516 is a clinical study titled "Prediction of ARrhythmic Events With Positron Emission Tomography II". Sudden cardiac death continues to be a major contributor to mortality in patients with ischemic cardiomyopathy. While implantable defibrillators can prevent death from ventricular arrhythmias, our current approach to identify patients at highest risk primarily rests on demonstrating a reduction in l...
What is the current status of trial NCT03493516?
This trial is currently active not recruiting. The enrollment target is 302 participants. The study started on 2018-04-08. Estimated completion is 2026-12-31.
What conditions does trial NCT03493516 study?
This clinical trial studies the following conditions: Congestive Heart Failure, Ischemic Cardiomyopathy, Sudden Cardiac Arrest.
What interventions are being tested in trial NCT03493516?
The interventions under investigation include: PET scan quantifying sympathetic denervation using [18F]-LMI1195 (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03493516?
This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03493516 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Congestive Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03493516's enrollment target sits among peer trials
302 15th of 51 higher than 37 of 51 other Congestive Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Congestive Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Palliative Care for People With HF
RECRUITING
-
Circulating Markers for Ischemic Heart Disease
RECRUITING
-
Stress and Congestive Heart Failure
RECRUITING · NA
-
Pharmacy-led Transitions of Care Intervention to Improve Medication Adherence
RECRUITING · NA
-
Care Transitions App for Patients With Multiple Chronic Conditions
RECRUITING · NA
-
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05722561 · 302 participants · Phase 2
E-Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder
- NCT06015737 · 302 participants · Phase 3
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
- NCT07176273 · 302 participants · NA
Adaptive Decision-making And Personalized Treatment for PTSD (ADAPT-PTSD)
- NCT05508971 · 303 participants · NA
Treatment of Obstructive Sleep Apnea With Personalized Surgery in Children With Down Syndrome (TOPS-DS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI